Inclusion Criteria. Subjects must meet all of the following criteria to be eligible to participate in this study: 1. The subject was enrolled, randomized to Abaloparatide-SC/Placebo and completed 18-months of blinded treatment within Study BA058-05-003. 2. The subject is no more than 40 days from Visit 9 in Study BA058-05-003. 3. The subject has read, understood, and signed the written informed consent form for the Extension Study.
Appears in 2 contracts
Samples: Clinical Trial Services Agreement (Radius Health, Inc.), Clinical Trial Services Agreement (Radius Health, Inc.)
Inclusion Criteria. Subjects must meet all of the following criteria to be eligible to participate in this study:
1. The subject was enrolled, randomized to Abaloparatide-SCBA058 Injection 80 µg/Placebo and completed 18-months of blinded treatment within Study BA058-05-003.
2. The subject is no more than 40 days from Visit 9 in Study BA058-05-003.
3. The subject has read, understood, and signed the written informed consent form for the Extension Study.
Appears in 2 contracts
Samples: Clinical Trial Services Agreement (Radius Health, Inc.), Clinical Trial Services Agreement (Radius Health, Inc.)
